Mould DP, Bremberg U, Jordan AM, Geitmann M, Maiques-Diaz A, McGonagle AE, Small HF, Somervaille TCP, Ogilvie D. (2017) Bioorg Med Chem Lett., 27:3190–3195.
A series of reversible inhibitors of lysine specific demethylase 1 (LSD1) with a 5-hydroxypyrazole scaffold have been developed from compound 7, which was identified from the patent literature. Surface plasmon resonance (SPR) and biochemical analysis showed it to be a reversible LSD1 inhibitor with an IC50 value of 0.23µM. Optimisation of this compound by rational design afforded compounds with Kd values of <10nM. In human THP-1 cells, these compounds were found to upregulate the expression of the surrogate cellular biomarker CD86. Compound 11p was found to have moderate oral bioavailability in mice suggesting its potential for use as an in vivo tool compound.
Sign up for the Beactica newsletter to receive our latest news and updates